Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

Thomas E. Witzig, Hui Tang, Ivana N.M. Micallef, Stephen M. Ansell, Brian K. Link, David J. Inwards, Luis F. Porrata, Patrick B. Johnston, Joseph P. Colgan, Svetomir N. Markovic, Grzegorz S. Nowakowski, Carrie A. Thompson, Cristine Allmer, Matthew J. Maurer, Mamta Gupta, George Weiner, Ray Hohl, Paul J. Kurtin, Husheng Ding, David LoegeringPaula Schneider, Kevin Peterson, Thomas M. Habermann, Scott H. Kaufmann

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Fingerprint

Dive into the research topics of 'Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds